IMO, the Rett trial is too small and too short to give us a good indication about future success or failure of 2-73. With 15 patients, there are probably 5 placebo patients, 5 low dose and 5 high dose. Likely 2-3 girls dropped out. 7 weeks is not a lot of time for any separation to occur between treated and untreated and also adults (age 16-45 Rett) might respond less than pediatric populations. As an example trofinetide had a trend for adults in a larger study (age 16-45 n = 67) but was significant for age 5-15 for Rett (n=82). So, maybe we see a difference which can be positively PR'd but significance is unlikely. Therefore, I feel a big pop large enough to do an offering is unlikely, though a 1.00-2.00 might still be seen.
PDD is much larger so a positive outcome could greatly move the stock and would also give a better indication of AD outcomes.
News 
Market Data 
Discover 
